Scott L. Burrows, the Chief Financial Officer of Spyre Therapeutics, Inc. (NASDAQ: SYRE), filed a report on June 25, 2026, detailing recent transactions involving the company's common stock. The executive executed a sale of 15,000 shares, resulting in gross proceeds of approximately $1,307,000. This divestiture was paired with a concurrent acquisition of 15,000 shares through the exercise of stock options.
The pricing for the executed sales ranged between $86.78 and $87.43 per share. Specific transaction details indicate that 5,000 shares were sold at $87.12 each. An additional block of 10,000 shares was sold at a weighted average price of $87.14. These figures reflect the market valuation of the company at the time of the transactions.
Before the sale was executed, Burrows exercised options to acquire 15,000 shares of Spyre Therapeutics common stock. The exercise price for these options was $14.50 per share, totaling $217,500. This option grant represents the right to purchase 404,857 shares of the company's common stock, a figure adjusted following the 1-for-25 reverse stock split implemented on September 8, 2023. The vesting schedule for these options stipulates that a quarter of the grants vested and became exercisable on September 1, 2024. The remaining portion of the options is scheduled to vest in monthly installments over the subsequent three years, contingent upon Burrows maintaining continued employment with the company.
Following the completion of these transactions, Scott L. Burrows directly holds a total of 97,994 shares of Spyre Therapeutics common stock. This aggregate holding includes 67,476 restricted stock units (RSUs). The vesting for these RSUs is structured to occur in two equal installments on September 1, 2026, and September 1, 2027, also subject to the condition of continued employment.
The timing of Burrows' transactions occurs against a backdrop of substantial movement in Spyre's share price. Over the past year, Spyre shares have surged by 477%. At the time of reporting, the stock was trading at $87.89, establishing a market capitalization of $7.62 billion. According to InvestingPro analysis, the stock appears overvalued relative to its Fair Value estimate, placing it among stocks on the most overvalued list. InvestingPro subscribers have access to 13 additional exclusive tips about SYRE's financial health and outlook.
In the broader context of the company's operations, Spyre Therapeutics has reported positive results from its phase 2 trial for the experimental drug SPY002, which targets ulcerative colitis. The trial, identified as SKYLINE, demonstrated a statistically significant improvement in patients' conditions. This marks a promising development for the company's pipeline. Additionally, Spyre completed enrollment for its SKYWAY basket trial, which is evaluating SPY072 in various rheumatic diseases. Results for different conditions from this trial are expected in 2026.
Analyst sentiment has responded to these developments with increased confidence in Spyre's prospects. Deutsche Bank raised its price target for Spyre to $115, maintaining a Buy rating, following a competitor's setback. Similarly, Stifel increased its price target to $107, also maintaining a Buy rating, based on strong data for SPY001 in ulcerative colitis. The market has also noted significant insider activity from other parties. Fairmount Healthcare Fund II L.P., affiliated with company directors, was reported to have sold all its shares in Spyre, valued at approximately $399.7 million.
These recent developments have attracted attention from investors and analysts, reflecting the company's ongoing activities and market dynamics. The interplay between clinical trial results, analyst upgrades, and executive stock transactions continues to shape the narrative around Spyre Therapeutics.